The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
...someone posting actual relevant stuff about this company, and medical cannabis related issues on a site meant for that be 'bluster,' Garry?
You're like a bitter ex. Give over.
This favourable biosynthetic shift from pro-inflammatory [lipid mediators] to inflammation-resolving SPM might be a plausible mode of action underlying the well-recognised anti-inflammatory properties of CBD and represents a molecular strategy to accomplish a local environment that is beneficial to promote inflammation resolution,’ they concluded.
Charles Serhan, an expert in infection and immunity at Harvard University in the US, describes the study as a ‘very important contribution’ as it brings together the cannabinoid field and the lipid mediators that play a role in the resolution of inflammation.
‘The group provides a mechanism for how the cannabinoids could evoke their well-known anti-inflammatory actions,’ he adds. ‘They clearly demonstrate that CBD switches off the pro-inflammatory mediators, the prostaglandins, produced by human M2 macrophages, and turns on the pro-resolving [mediators].’
But he said the ‘critical question’ was whether this can be demonstrated in a human trial. ‘A study like this will open the door for that possibility,’ he says.
Clive Page, an expert in the pharmacology of inflammation based at King’s College London, says it is increasingly recognised that CBD is not just a compound that affects cannabinoid receptors but has activity on a wide range of receptors.
‘The interesting thing [in this study] is that CBD is switching to the production of molecules that actually resolve the inflammation; that’s what happens physiologically…it’s when it doesn’t resolve that you end up with chronicity.’ Page agreed with Serhan that placebo-controlled trials of CBD in the clinic are now needed.
‘What we desperately need, and what is missing from the literature, is proper evidence in clinical trials…this paper effectively just adds more to the literature that we should be taking CBD seriously because, unlike THC from cannabis, it doesn’t have psychoactive effects and… it’s got a reasonable safety track record,’ Page adds. ‘What we’ve got to do is tease out the right dose for the right indication.’
They were able to determine that CBD acts as a potent lipid-mediator class-switching agent in innate immune cells, shifting the formation of pro-inflammatory compounds, such as leukotrienes and prostaglandins, to inflammation-resolving specialised pro-resolving mediators (SPMs). These SPMs are potent endogenous anti-inflammatory compounds that function in host defence, pain and organ protection.
Their analysis showed that CBD directly suppressed formation of a leukotriene while also activating a lipoxygenase enzyme, triggering a change from pro-inflammatory molecules to inflammation-resolving SPMs.
The researchers were able to confirm that cannabinoids suppressed leukotriene formation and increased SPM production in a mouse model of peritonitis.
Currently, the major therapeutics to treat inflammation-related diseases are glucocorticoids and non-steroidal anti-inflammatory drugs. However, while these agents dampen inflammation and immune responses they fail to promote inflammation resolution, and they also frequently cause severe side effects. The researchers therefore said the mechanism of action exhibited by CBD represented an ‘alternative strategy with potential for pharmacotherapy of unresolved inflammation’.
The molecular basis for the anti-inflammatory properties of cannabidiol (CBD) has been discovered that suggests that the compound not only inhibits inflammation but also helps to resolve it. The researchers say the insights gained could lead to new therapeutic strategies for treating inflammatory diseases.
Cannabis and cannabinoids, especially CBD, are well-recognised anti-inflammatory agents that are increasingly popular for treating inflammation-related disorders such as inflammatory bowel diseases and skin disorders. However, although several potential modes of action and molecular targets have been proposed, the exact mechanism by which they work is yet to be confirmed.
The researchers studied how eight different cannabinoids, including CBD and the psychoactive tetrahydrocannabinol (THC), act on human immune cells. All had anti-inflammatory effects and were found to inhibit the formation of pro-inflammatory messenger substances in cells while enhancing the formation of inflammation-resolving substances.
However, they discovered that CBD was the most potent anti-inflammatory of the cannabinoids and decided to investigate the compound in more detail.
The anti-inflammatory properties of cannabidiol (CBD) are well established, but as Ananda Non-Executive Director Professor Clive Page notes in this article, more clinical research is needed.
View organization page for Ananda Developments Plc
Ananda Developments Plc
1,320 followers
2h Edited
It is great to see the UK Government taking endometriosis seriously. The 1.5 million women who suffer from this condition desperately need better support.
Part of delivering better support is investing more in research and clinical trials to develop new, more effective treatments that don't have the same adverse side effects as many existing treatments.
Ananda believes that cannabinoid medicines could play a critical role in managing the pelvic pain associated with endometriosis. That is why we are providing one of our cannabidiol (CBD) oil formulations to a Phase II randomised controlled trial with The University of Edinburgh to target the treatment of pelvic pain in suffers of endometriosis. The trial is being supported with £300,000 of grant funding from the Chief Scientist Office, the research funding arm of NHS Scotland.
As per RNS the growing side has been paused, not stopped. There's no point continuing with something that's going to be running potential losses atm when they can focus elsewhere. In some ways imo it's likely that the government and regulatory framework is behind what these medical cannabis companies want to do. And every British govt, no matter its colour, is notoriously lazy when it comes to alternative medicines and even some mainstream ones. If there's no Big Pharma involvement right away, there appears to be little Westminster motivation. Having said that, the med cann direction of travel with results and feedback is clearly strong. It's like AI, it's not going to go away.
I don't like where the sp sits, I don't like the lack of promo from the company, I don't like their sometimes flaky RNSs. I do like that there's a lot going on here and clinical trial results and promo are on the horizon. Yes it will be a slow burner. I accept that things take time, yes you need balls of steel.
And one of the main problems ANA will have is moving to AIM and then finding they will come in for a ramped-up bunch of attacks by financial trolls who, if not already aware, will work out that their company structure is deeply skewed towards the directors. They'll get more flak under the AIM spotlight out of this quiet corner of Aquis. The retail scraps could be decent to very decent returns imo, with time, so that's ultimately the hope. If clinical trial results are good we should start to see this get onto more radars. And there's a presentation coming in November I believe. But yes, it is simply a slow burner. They don't always get it right, but neither are they struggling or out of ideas. Far from it it seems.
Very slow burner. Maybe 5 or ten years for a return. In the meantime: Ana Developments. Should be Ana Development: seem like a one club golfer now, I'm afraid. Would be more encouraging if we heard more about think tank and lobbying taking place to further change the HMG mindset about cannabis and how Ana is linking with this. Who's ears at HMG are ANA bending, directly or indirectly, to get NHS prescribing started?
Research continues to uncover the molecular basis for the incredible anti-inflammatory properties of cannabidiol (CBD). However, as Ananda Non-Executive Director Professor Clive Page notes in this article, more clinical research is needed:
"What we desperately need, and what is missing from the literature, is proper evidence in clinical trials…What we’ve got to do is tease out the right dose for the right indication."
Ananda is hopeful that the two Phase II clinical trials we are providing our cannabidiol oil formulation to at the The University of Edinburgh will demonstrate the efficacy of CBD for treating the pain associated with endometriosis and chemotherapy induced peripheral neuropathy.
To keep up with Ananda news subscribe via our website at https://lnkd.in/eY7tA55S.
Pretty Amazing that Professor clive Page is on our board too and for him to feel that we are worthy too of his name to be associated with us as well!
I Guess he has seen something special too within Ananda on how we have approached and engaged in the sector and progressed in such an efficient manner
Pretty amazing really that Ananda are a stand out company selected to carry out these two trials I'd say and the prospects afterwards could be mind blowing
Lol most people call it stating the facts
And as we know links cannot be posted!
Next question before I'm filtered for ever even though you could of done this prior to now
Are you still here Gary. Why don’t you do us all a favour and just sell up and stop bothering us all! You are very dull!
The ACMD seeks to provide scientific, evidence-based recommendations to support the development of evidence-based drug policy.”
In conclusion, a turning point is near for the UK’s medical cannabis industry. Although we can see many succeses since cannabis reschedule in 2018, there are still present obstacles. The UK has the ability to offer beneficial medical cannabis solutions for individuals in need while navigating the complex web of legislation, access, and awareness with a dedication to research, accessibility, and patient-centric policy.
Nevertheless, the Scottish NHS has already supported the UK medical cannabis company – Ananda Developments. Thanks to this cooperation, they will be able to mark a notable advance in endometriosis pain management with their new MRX1 cannabinoid oil.
Author: Daria B
RELATED
Greece: Largest facility of medical cannabis in Europe
MEDICAL, TECHNOLOGY & PRODUCTION
Sanity Group: “avaay SIGNATURE” medical cannabis line
BUSINESS, MEDICAL
Working thanks to cannabis? New study challenges stereotypes
MEDICAL, SCIENCE
POPULAR
The crucial role of pesticides testing in cannabis cultivation
TECHNOLOGY & PRODUCTION
The cannabis case: why WADA upholds the ban in sport?
LAW, SCIENCE
Cannabidiol (CBD) as an anti-inflammatory and antibacterial agent for acne treatment
SCIENCE
EVENTS
CannabizEU logo
Linkedin Twitter Facebook
ABOUT US
PRIVACY POLICY
FAQ
ADVERTISE
CONTACT US
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assu
In a world where financial assets are yielding lower and lower returns, and healthcare costs are skyrocketing, the pharmaceutical sector stands on a fertile ground of innovation and untapped market potential.
Armed with an unprecedented $700 billion for acquisitions and investments, as reported by Goldman Sachs, pharma companies are eyeing new avenues for growth. One sector that’s seeing a flurry of clinical activity is cannabis, supported by more than 400 ongoing clinical trials and newfound regulatory support.
As pharma executives and life science investors navigate through a world of possibilities, the question arises: Is cannabis the high-growth sector that Pharma has been waiting for?
High-risk, high-reward gamble it once was—it’s an emerging market with strong scientific backing.
Investing in cannabis could yield not just significant ROI but also add a diversified asset to the portfolio. After all, as any seasoned investor knows, the key to thriving in an increasingly volatile global market is diversification. In this rapidly changing healthcare landscape, cannabis appears to be one of the most promising sectors ripe for investment and innovation.
Conclusion
With the stars aligning in favour of cannabis—be it regulatory support, mounting clinical evidence, or untapped market potential—it’s time for the pharmaceutical industry to take a serious look at this burgeoning sector. With $700 billion at their disposal, pharma companies have the financial power to drive unprecedented innovation and growth in cannabis, potentially revolutionizing healthcare as we know it.
For those looking to stay ahead of the curve, cannabis offers not just a business opportunity but a chance to be part of a healthcare transformation.
Pulse
A diverse BOD's with a finger on the sectorial post making a ballsy change to suit timing and immediate focus to underpin its future!
Ananda will present at the Aquis Exchange Showcase event at the Royal College of Surgeons in London on the 28 November 2023. If you are interested to hear from us as well as a range of guest speakers, save the date and contact AQSEBusinessDevelopment@aquis.eu for more information.
[LINK REMOVED]
GoodCap Pharmaceuticals Announces Publication of Positive Results from Two Studies Relating to GoodCap's Lead Drug Candidate
Toronto, Ontario--(Newsfile Corp. - September 12, 2023) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), a leading biopharmaceutical company focused on discovering and developing novel anti-inflammatory treatments for mood-disorders, today announced the publication of two manuscripts. These studies explore groundbreaking approaches to treating the broad symptomology associated with Post-Traumatic Stress Disorder (PTSD) by targeting the underlying factors of chronic inflammation and oxidative stress. Links to the manuscripts can be found here:
[LINK REMOVED]
[LINK REMOVED]
"As we continue our pursuit to enhance the lives of those affected by PTSD, these publications validate the innovative nature of our research and its potential to revolutionize treatment paradigms," said Dr. Darryl Hudson, Co-Founder and Chief Innovation Officer at GoodCap. "Our multi-faceted approach to tackle the root causes of PTSD symptoms, namely chronic inflammation and oxidative stress, sets us apart in a market that has an enormous unmet need for more effective treatments."
The studies provide evidence that GoodCap's novel drug candidate is effective in modulating key biochemical pathways, thereby reducing inflammation. These mechanisms are believed to be fundamental drivers of PTSD's broad symptomology and an underlying factor for a variety of ailments including cancers, gastro-intestinal diseases, and age-related diseases.
"We are very encouraged by the outcomes of these studies," said Steven Sadoff, Co-Founder and CEO of GoodCap. "They represent significant milestones in our development program and bring us closer to providing a transformative treatment for PTSD and beyond."
GoodCap Pharmaceuticals is currently preparing to enter into human-use trials in 2024. "As we forge ahead into the next stages of our development program, the evidence presented in these studies strengthens our resolve," said Dr. Hudson. "We are committed to accelerating the process to bring these novel therapies to market, thereby offering renewed hope for the hundreds of millions suffering from PTSD."
About GoodCap Pharmaceuticals Inc.
GoodCap, a privately held biopharmaceutical research and development company, is a leader in the development of therapies that target both inflammation and oxidative stress. GoodCap believes that chronic inflammation and oxidative stress are major comorbidities and contributors to indications such as PTSD, depressive disorders, and age-related diseases, and is developing treatments that simultaneously target both pathologies.
Clive Page is a Professor of Pharmacology, King’s College London and Director of The Pulmonary Pharmacology Unit, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of Babraham Biotechnology Ltd, as well as being a Trustee of the Babraham Institute in Cambridge and a Non Executive Director of the Board of ImmunoRegulation Ltd, PreP Biopharma and EpiEndo.
Can CBD or CBD oil help treat endometriosis? Yes, CBD oil can help treat some patients with endometriosis. Endometriosis causes major inflammation which is one of the reasons that individuals experience pain. CBD and CBD oils are known to have anti-inflammatory properties.
What's helping to manage that pain going to be worth.......